TLC 144
Latest Information Update: 30 Jul 2002
At a glance
- Originator The Liposome Company
- Class Antineoplastics
- Mechanism of Action Apoptosis stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 28 Jul 2000 Preclinical development for Cancer in USA (Unknown route)
- 31 May 2000 The Liposome Company has been acquired by Elan Corporation